VIE/HPHA (VIE/HPHA)

Vienna Stock Exchange: VIE/HPHA · EUR

€2.15

+0.01 (+0.5%)· Recorded snapshot

Market cap	100.1M
Revenue (ttm)	9.3M
Net income (ttm)	-29.9M
EPS (ttm)	-€0.66

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 9.3M
Net income (ttm): -29.9M
EPS (ttm): -€0.66
Market cap: 100.1M

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-30 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All VIE/HPHA indicators

Market & fundamental data

Available fields

150

Groups with data

Currency

EUR

Showing 150 of 150 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	EUR
Country	Germany
Country code	AT
Earnings date	2027-03-24
Employees	33
Employees change	-78
Employees growth	-70.27%
Enterprise value	EUR 80.6M
Exchange	Vienna Stock Exchange
Financial currency	EUR
Financial report date	2026-08-31
First seen	2026-07-12
Fiscal year end	November
Founded	1997
Industry	Biotechnology
Is primary listing	No
ISIN number	DE000A11QVV0
Last earnings date	2026-07-15
Last refreshed	2026-10-30
Market cap	EUR 100.1M
Next earnings date	2027-03-24
Price	EUR 2.15
Price currency	EUR
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-29
Symbol	vie/HPHA
Website	https://heidelberg-pharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-30.54%
EV/Sales	8.65x
FCF / EV yield	-23.72%
FCF yield	-19.09%
P/S ratio	10.74x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	80.93%
Operating margin	-352.32%
Pretax margin	-305.08%
Profit per employee	EUR -906,166
Revenue per employee	EUR 282,370
ROA	-42.36%
ROA (5Y)	-39.93%
ROCE	-93.97%
ROE (5Y)	-165.62%
SBC / revenue	0.54%
Tax / revenue	15.83%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	3
EPS growth years	0
Gross profit growth	193.26%
Gross profit growth 3Y	3.08%
Net income growth quarters	3
Net income growth years	0
Revenue growth	206.78%
Revenue growth (Q)	3,974.11%
Revenue growth (QoQ)	-55.81%
Revenue growth 10Y	16.1%
Revenue growth 3Y	-0.48%
Revenue growth 5Y	43.77%
Revenue growth quarters	3
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	EUR 28,973
Depreciation and amortization	EUR 259,844
EBIT	EUR -32.8M
EBITDA	EUR -32.6M
EPS	EUR -0.66
Financing cash flow	EUR 16.6M
Free cash flow	EUR -19.1M
Free cash flow minus SBC	EUR -19.2M
Gross profit	EUR 7.5M
Income taxes	EUR 1.5M
Investing cash flow	EUR 726,187
Net borrowing	EUR -182,275
Net cash flow	EUR -3M
Net income	EUR -29.9M
Operating cash flow minus SBC	EUR -19.2M
Operating income	EUR -32.8M
Revenue	EUR 9.3M
Stock-based compensation	EUR 50,026

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-12.79
Book value per share	EUR -0.44
Goodwill	EUR 6.1M
Interest coverage	-6,569.89
Long-term assets	EUR 9.4M
Long-term liabilities	EUR 54.3M
Net cash (debt)	EUR 19.5M
Net cash / market cap	19.52%
Net cash growth	-14.06%
Piotroski F-Score	2
Property, plant and equipment	EUR 430,104
Shareholders' equity	EUR -19.3M
Tangible book value	EUR -28.1M
Tangible book value per share	EUR -0.65
Total assets	EUR 42.8M
Total cash	EUR 19.8M
Total debt	EUR 298,958
Total liabilities	EUR 62.1M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.19
Current assets	EUR 33.4M
Current liabilities	EUR 7.9M
Current ratio	4.24
Inventory turnover	0.14
Net working capital	EUR 5.8M
Quick ratio	2.96
Working capital	EUR 25.5M
Working capital turnover	0.31

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	2.91%
Shareholder yield	2.91%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1D price change	0.47%
1M price change	-15.35%
1M total return	-15.35%
1W price change	0.47%
1W total return	0.47%
20-day SMA	EUR 2.21
3M price change	-16.34%
3M total return	-16.34%
50-day SMA	EUR 2.38
52-week high	EUR 2.84
52-week high date	2026-04-28
52-week low	EUR 1.99
52-week low date	2026-10-22
6M price change	-22.94%
6M total return	-22.94%
All-time high	EUR 2.84
All-time high date	2026-04-28
All-time low	EUR 1.99
All-time low date	2026-10-22
Average true range (ATR)	EUR 0.06
Average volume	84
Change from 52-week high	-24.3%
Change from 52-week low	8.04%
Change from all-time high	-24.3%
Change from all-time low	8.04%
Change from open	0.47%
Day's gap	0%
High price	EUR 2.15
Low price	EUR 2.14
Monthly RSI	0
Open price	EUR 2.14
Position in 52-week range	100%
Previous close	EUR 2.14
Price vs 20-day SMA	-2.8%
Price vs 50-day SMA	-9.82%
Relative volume	15.88
RSI	39.99
Sharpe ratio	-1.78
Sortino ratio	-2.03
Weekly RSI	34.17

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	10M
Shares change (QoQ)	-5.73%
Shares change (YoY)	-2.91%
Shares held by insiders	2.31%
Shares held by institutions	0.73%

Deeper analysis on VIE/HPHA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this VIE/HPHA report

Is a complete VIE/HPHA research report available?

No complete published report is available for vie/HPHA (VIE/HPHA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

VIE/HPHA (VIE/HPHA)

Price

Financial snapshot

Fair-value bridge

Latest news · VIE/HPHA

Valuation

Profitability

Balance sheet

Next earnings

Sector percentile context

All VIE/HPHA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on VIE/HPHA

Frequently asked questions